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Immunoactivating Peptide P4 Augments Alveolar Macrophage
Phagocytosis in Two Diverse Human Populations
Mathieu Bangert,a,d Adam K. Wright,a Jamie Rylance,b Matthew J. Kelly,b Angela D. Wright,a George M. Carlone,c
Jacquelyn S. Sampson,c Gowrisankar Rajam,c Edwin W. Ades,c Aras Kadioglu,d Stephen B. Gordona
Respiratory Infection Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdoma; Malawi-Liverpool-Wellcome Clinical Research Laboratories, Blantyre,
Malawib; Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USAc; Clinical Infection, Microbiology and Immunology, Institute of
Infection & Global Health, University of Liverpool, Liverpool, United Kingdomd
New treatment strategies are urgently needed to overcome early mortality in acute bacterial infections. Previous studies have
shown that administration of a novel immunoactivating peptide (P4) alongside passive immunotherapy prevents the onset of
septicemia and rescues mice from lethal invasive disease models of pneumococcal pneumonia and sepsis. In this study, using two
diverse populations of adult volunteers, we determined whether P4 treatment of human alveolar macrophages would upregulate
phagocytic killing of Streptococcus pneumoniae ex vivo. We also measured macrophage intracellular oxidation, cytokine secre-
tion, and surface marker expression following stimulation. Peptide treatment showed enhanced bacterial killing in the absence
of nonspecific inflammation, consistent with therapeutic potential. This is the first demonstration of P4 efficacy on ex vivo-de-
rived human lung cells.
The rate of early mortality from severe pneumonia and sepsis ishigh in developed and developing countries. Antibiotic treat-
ment alone is inadequate for severe infections, as treatment has
not been shown to reduce deaths that occur in the initial 48-hour
period following admission (1). To bridge this treatment window,
augmented passive immunotherapy (API) is a potential new treat-
ment paradigm that uses the concurrent administration of an im-
munoactivating peptide (P4) to enhance phagocytosis with
pathogen-specific antibodies in pooled immunoglobulin (IVIG).
P4 is a 28-amino-acid (aa) peptide derived from the functional site
of the Streptococcus pneumoniae pneumococcal surface adhesion
A protein (PsaA) (2).Murinemodels of acute infection have dem-
onstrated the therapeutic benefits of API administered by either
intranasal or intravenous routes. Such treatment has been dem-
onstrated to rescuemice from invasive pneumonia (3, 4), influen-
za-pneumonia coinfections (5), and methicillin-resistant Staphy-
lococcus aureus (MRSA) (6), independent of age (7) and strain
background (8), although to date there are no data from human
lung samples. Since P4 peptide treatment of Streptococcus pneu-
moniae (pneumococcus)-infected murine lungs prevented the
onset of sepsis and subsequent hostmortality (4), we hypothesized
that ex vivo P4 treatment of human alveolar macrophages would
lead to enhanced phagocytic function with no or limited general-
ized inflammation.
To test this hypothesis, healthy adult volunteers were recruited
to a study in Liverpool (United Kingdom) and Blantyre (Malawi)
involving bronchoscopy and bronchoalveolar lavage (BAL). Eth-
ical approval was obtained from the National Health Service Re-
search Ethics Committee (11/NW/0011) and the Malawi College
of Medicine Ethics committee (P.03/11/1063). The median age of
United Kingdom volunteers was 25.6 years  9.5 (8 females, 6
males) and that of Malawian volunteers was 31.4 years 3.3 (11
females, 2 males). Alveolar macrophages were isolated from BAL
fluidcollectedduringbronchoscopybyadherenceandwashing steps,
resulting in95% alveolarmacrophage purity. An opsonophagocy-
tosis killing assay (OPKA) was then performed as previously de-
scribed (3) with minor modifications. Briefly, 1 105 macrophages
were allowed to phagocytose IVIG-opsonized Streptococcus pneu-
moniae strain D39-ST2 (IVIG final dilution, 1:32; multiplicity of in-
fection, 1:100) in the presence of complement for 2 h. P4 peptide
solution (10l of 1mg/ml solution)was added to theOPKAmixture
following the preopsonization stage, and CFU were cultured from
supernatants following a 2-h incubation.Abacterial killing indexwas
established by comparing the number of pneumococci recovered af-
ter OPKA to the number of pneumococci added. In some reactions,
Fc receptors were occupied using human IgG prior to OPKAs to
assess the involvement of Fc receptors during P4-augmented
phagocytosis. In linewith previous data onmurinemacrophages (4),
peptide stimulation of human alveolar macrophages led to signifi-
cantly enhancedbacterial killing inboth theUnitedKingdom(40.1%
killing for control versus 68.2% killing for P4 treated; P  0.001,
analysis of variance [ANOVA]; n  14 volunteers) and Malawian
(35.8% killing for control versus 47.6% for P4 treated; P  0.01,
ANOVA; n  13 volunteers) populations (Fig. 1A). In contrast,
phagocytosis in the absence of antibody or complementwas reduced
to 10.8% or 20.1%, respectively, and no detectable differences be-
tweenstimulatedandnonstimulatedgroupswere seen(n6;United
Kingdom population). Similarly, macrophages in which Fc recep-
tors were occupied following stimulation showed reduced phagocy-
tosis (23.3%), and no detectable differences between stimulated and
nonstimulated groupswere seen (Fig. 1B). There is therefore a neces-
sity for all components involved in phagocytosis (immunoglobulin,
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complement, phagocytic receptors) to be present for P4 treatment to
be effective.
Alveolar macrophages respond to stimuli and infection with
increased oxidative metabolism. We assessed whether peptide
treatment would alter intracellular oxidation in the presence and
absence of immune complexes using a technique previously de-
scribed (9). Briefly, alveolar macrophages were first incubated
with 2=,7=-dichlorofluorescein-diacetate (DCFH-DA), followed
by lipopolysaccharide (LPS) (100 g/ml solution; Sigma, United
Kingdom) or P4 solution (10 l of 1 mg/ml solution). Intracellu-
lar oxidation was then measured using a microplate reader (BMG
Labtech, United Kingdom). The assay was also performed with
opsonized pneumococci to measure intracellular oxidation in re-
sponse to P4-mediated phagocytosis. P4 treatment of alveolar
macrophages exposed to opsonized bacteria and complement
(n 6; United Kingdom population) led to a significant increase
FIG 1 (A)Opsonophagocytosis killing assay (OPKA) using human alveolarmacrophages from healthy volunteers recruited in Liverpool, United Kingdom (n
14), and Blantyre, Malawi (n 13); (B) OPKA of United Kingdom volunteers (n 6), where “OPK” designates assays in which all components are included
(macrophage, bacteria, antibody, complement), “no antibody” designates assays without the presence of antibody, “no complement” designates assays without
the presence of complement, and “FcR block” designates assays where Fc receptors were occupied by IgG prior to the assay; (C) intracellular oxidation of
alveolar macrophages (n  6; United Kingdom population) during an opsonophagocytosis assay in the presence (OPKAP4) or absence (OPK) of peptide
stimulation; (D) intracellular oxidation in the presence of PBS, LPS (100g/ml), or P4 (1mg/ml) alone; (E) cytokine levels detected in OPKA supernatant using
a BD Flex Set kit following a 2-hOPKA; (F) surfacemarkers of activation on control or P4-activated alveolarmacrophages (n 6) following a 2-hOPKA, stained
and analyzed using flow cytometry.
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in fluorescence (oxidation) compared to that of the control (135%
for the treated versus 81% for the control at 140 min; P  0.05,
ANOVA; n 6) (Fig. 1C). Direct stimulation of alveolar macro-
phages by P4 peptide in the absence of an immune complex, how-
ever, showed no statistical difference (102% for treated versus
84% for control at 160 min; P 0.30, ANOVA) (Fig. 1D). Direct
stimulationwith LPS alone, in comparison, significantly increased
intracellular macrophage oxidation compared to that of non-
treated control cells (139% for LPS treated versus 84% for control
at 160 min; P  0.05, ANOVA). In addition, using detergent to
burst open cells following OPKA, we found2% of the inoculum
intracellularly, with no significant difference between stimulated
and unstimulated control macrophages (data not shown). These
data together suggest that peptide stimulation also leads to effec-
tive breakdown of internalized pneumococci.
Since peptide stimulation of alveolar macrophages enhanced
bacterial killing and intracellular oxidation, we investigated
whether peptide treatment would alter expression of surface
markers and the release of cytokines during an OPKA. Following
OPKA, alveolar macrophages were stained using optimal concen-
trations of anti-HLA-DR antibody (major histocompatibility
complex class II [MHC-II]; 560743), CD206 (mannose receptor;
55089), CD11b (integrin; 347557), CCR7 (chemokine receptor;
557648), CD163 (activation marker; 556018), and CD86 (activa-
tion marker; 555657), and supernatants were analyzed using the
BD cytokine bead array kits for soluble proteins (BD-CBA Flex
Sets) according to the manufacturer’s instructions. Following a
2-h incubation with opsonized pneumococci and complement,
alveolar macrophages (n 11; United Kingdom population) did
not significantly alter their secretion of inflammatory cytokines,
MIP-1	, monocyte chemoattractant protein 1 (MCP-1), interleu-
kin 10 (IL-10), IL-12, gamma interferon (IFN-), tumor necrosis
factor alpha (TNF-
), or CCL5 when stimulated with P4 (P 
0.1). A slight increase of IL-8 (P 0.08), MIP-1
 (P 0.1), and
IL-6 (P 0.1)was detected following peptide stimulation, but this
was not statistically significant. Similarly, following a 2-h incuba-
tion in anOPKA, P4-treated alveolarmacrophages (n 6; United
Kingdom population) did not express higher levels of HLA-DR,
CD206, CD11b, CCR7, CD163, or CD86 than control cells (P 
0.1). These data suggest that P4-enhanced phagocytic killing does
not induce changes in the activation profile of alveolar macro-
phages (Fig. 1E and F).
Previous work has shown that targeting effector cells during
pneumonia via direct peptide administration to affected lungs en-
hances the clearance of infection and prevents the onset of septi-
cemia (4). During pneumonia, neutrophils and alveolar macro-
phages are the predominant responding phagocytes. We have
previously shown that humanperipheral bloodneutrophil phago-
cytosis is augmented following peptide stimulation (3), and here
we present the first data showing human alveolar macrophages,
critical to lung defense, responding to peptide stimulation. In this
study, alveolarmacrophages from bothUnited Kingdom andMa-
lawian volunteers showed a significant increase in bacterial killing
and intracellular oxidation as a result of peptide treatment. Two
diverse human populations with different levels of susceptibility
to pneumococcal disease were deliberately compared. United
Kingdom adults of the age recruited have a low incidence of pneu-
monia (1/1,000/year) and pneumococcal carriage (10%), but
in Malawi, disease incidence is significantly higher, due to greater
exposure and risk factors, including malnutrition, smoke expo-
sure, and concurrent infections (10).
In summary, we have shown that P4 peptide treatment of hu-
man alveolar macrophages led to a significant increase in their
ability to phagocytose opsonized pneumococci. Importantly, we
show P4 efficacy in two diverse human populations with differing
levels of susceptibility to pneumococcal disease. These data are
consistent with rescue from pneumonia and sepsis, as demon-
strated in murine models. Our findings are important, as early
treatment options for severe sepsis are urgently needed, and API
offers a new paradigm for treatment of invasive diseases such as
sepsis. As API is an antibody-driven treatment, in the presence of
effective opsonization, peptide stimulation will lead to enhanced
phagocytosis irrespective of the pathogen. Opsonization occurs
through the broad specificity of IVIG, and the formed immune
complexes are effectively cleared through the effects of peptide
stimulation (including modulation of phagocytic Fc receptors)
on phagocytes (4, 5). This has the potential to rapidly assist an
infected patient prior to diagnostic results and antibiotic efficacy.
We envisage P4 and immunoglobulin administration as part of an
adjunct therapy with antibiotic treatment, a strategy that has pre-
viously been shown to rescuemicewith lethal invasive pneumonia
(8).
To our knowledge, this is the first demonstration of exogenous
peptide treatment leading to increased opsonophagocytosis of
bacteria by human alveolar macrophages. Together with our pre-
vious studies, we have now shown that P4 therapy is highly effec-
tive in stimulating major phagocytes involved in defending
against pneumonia and sepsis in both in vitro human and in vivo
murine studies. Augmented passive immunotherapy is a promis-
ing new strategy for clinical testing within a broad range of patient
groups suffering from respiratory infections.
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